NIH suspends new embryonic stem cell line submissions

The Directors: Gary Schwartz and Ramon Parsons on the best of times (for science), the worst of times (for funding)
Cancer centers fund small grants to boost morale amid low paylines

As NCI paylines drop to 4%, cancer centers are tapping into their institutional funds to provide “bridge funding,” typically in $50,000 to $100,000 increments, to enable investigators to keep their labs open until better times return—next year God willing.

January 30, 2026

Vol.52 No.04

By Paul Goldberg and Claire Marie Porter

Capitol Hill

Spending bill passed by the House gives NIH $415M raise, NCI gets $128M
Legislation caps proportion of NIH grants to receive multiyear funding; indirect costs remain untouched

The U.S. House of Representatives Jan. 22 passed a three-bill minibus package that is expected to be the grand finale of the drama of the fiscal year 2026 appropriations process. The package, which funds the HHS as well as the departments of Defense, Transportation, Housing and Urban Development, Labor, and Education, gives NIH and NCI modest raises over FY25, and nullifies several aggressive cuts the White House had proposed for NIH.

NIH ends fetal tissue research—again

NIH will no longer fund scientific research that uses human fetal tissue from elective abortions, a practice that has contributed to the study of cancer, the development of vaccines, and the treatment of other diseases.

NIH agrees to review hundreds of denied or shelved grant applications

Last year, the Trump administration began dismantling, RIFing, and stamping out programs and staff deemed ideological or politically motivated, halting application processes, and stripping funding opportunities.

January 09, 2026

Vol.52 No.1

By Claire Marie Porter

NCI

In first NCAB director’s report, Anthony Letai focuses on centralized grant review, budget outlook

Anthony G. Letai’s initiation as the 18th director of the National Cancer Institute wasn’t exactly smooth.

FDA releases draft guidance on reducing testing on non-human primates for monoclonal antibodies

FDA issued a draft guidance on Dec. 2, outlining specific product types for which the FDA believes six-month non-human primate toxicity testing can be eliminated or reduced.

December 05, 2025

Vol.51 No.44

By Jacquelyn Cobb

NIH suspends new embryonic stem cell line submissions

YOU MAY BE INTERESTED IN

The Directors: Gary Schwartz and Ramon Parsons on the best of times (for science), the worst of times (for funding)
Cancer centers fund small grants to boost morale amid low paylines

Spending bill passed by the House gives NIH $415M raise, NCI gets $128M
Legislation caps proportion of NIH grants to receive multiyear funding; indirect costs remain untouched

NIH ends fetal tissue research—again

NIH agrees to review hundreds of denied or shelved grant applications

In first NCAB director’s report, Anthony Letai focuses on centralized grant review, budget outlook

FDA releases draft guidance on reducing testing on non-human primates for monoclonal antibodies

Renew today!

Subscriber content

Never miss an issue!

Login

NIH suspends new embryonic stem cell line submissions

YOU MAY BE INTERESTED IN

The Directors: Gary Schwartz and Ramon Parsons on the best of times (for science), the worst of times (for funding)Cancer centers fund small grants to boost morale amid low paylines

Spending bill passed by the House gives NIH $415M raise, NCI gets $128MLegislation caps proportion of NIH grants to receive multiyear funding; indirect costs remain untouched

NIH ends fetal tissue research—again

NIH agrees to review hundreds of denied or shelved grant applications

In first NCAB director’s report, Anthony Letai focuses on centralized grant review, budget outlook

FDA releases draft guidance on reducing testing on non-human primates for monoclonal antibodies

Never miss an issue!

Login

The Directors: Gary Schwartz and Ramon Parsons on the best of times (for science), the worst of times (for funding)
Cancer centers fund small grants to boost morale amid low paylines

Spending bill passed by the House gives NIH $415M raise, NCI gets $128M
Legislation caps proportion of NIH grants to receive multiyear funding; indirect costs remain untouched